Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data
02:10am, Sunday, 31'st Mar 2024
Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as El
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
10:31am, Friday, 29'th Mar 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
International Companies Drive Diabesity Innovation
09:59am, Friday, 29'th Mar 2024
International Companies Drive Diabesity Innovation
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
03:02pm, Thursday, 28'th Mar 2024
The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could
2 Top Biotech Buyout Candidates
02:56pm, Thursday, 28'th Mar 2024
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i
Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone
01:28pm, Thursday, 28'th Mar 2024
As the stock market rally continues, the trillion-dollar market cap club stands to get just a bit more crowded. Undoubtedly, more than a handful of mega-cap titans could pass the $1 trillion milestone
Wegovy will be covered by some insurers, but not for weight loss: report
09:55am, Thursday, 28'th Mar 2024
Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street
Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy
05:18pm, Wednesday, 27'th Mar 2024
Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the “
Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests
12:55pm, Wednesday, 27'th Mar 2024
Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.
Missed out on Eli Lilly and Novo Nordisk? This pharma stock could be the next ‘big thing'
10:05am, Wednesday, 27'th Mar 2024
Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have
Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
06:26am, Wednesday, 27'th Mar 2024
The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina
3 Stocks to Buy for the Next Bull Run: March 2024
12:09pm, Tuesday, 26'th Mar 2024
As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
12:01pm, Tuesday, 26'th Mar 2024
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
Wall Street Awaits Consumer Confidence Data
11:26am, Tuesday, 26'th Mar 2024
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
05:51am, Tuesday, 26'th Mar 2024
Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa
